Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Tag: Dual orexin receptor antagonist

Suvorexant

Plain-language summaryIntrigue 78 / 100

Suvorexant, sold as Belsomra, is a dual orexin receptor antagonist (DORA), the first of a new sleep medication class. Unlike GABAergic hypnotics it works by blocking the wakefulness-promoting orexin system. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

57/100

First-in-class DORA with a clean mechanistic story, but the novelty window has closed

Suvorexant was genuinely exciting when Merck cleared the FDA in 2014. It was the first commercialized DORA, and that represented a clean conceptual break from the GABAergic sedative tradition that had dominated sleep pharmacology for decades. Instead of dampening CNS excitability broadly, it blocks orexin-A and orexin-B at both OX1R and OX2R, removing the active drive to wakefulness rather than forcing sedation. Thats a real mechanistic contribution, and it’s still the reason the DORA class earns serious bench attention at all.

Here’s the thing though: that novelty window is essentially closed. Suvorexant has been on market twelve years. The pivotal METEOR and SORReL trials are thoroughly characterized. Lemborexant came in with a sharper half-life profile, daridorexant demonstrated competitive tolerability data in phase 3, and suvorexant is now the reference standard in a maturing class rather than the frontier of it. The 12-hour plasma half-life driven by CYP3A4 clearance creates morning residual sedation concerns that newer entrants specifically addressed. A bench scientist choosing a DORA probe today has reasons to reach past suvorexant rather than defaulting to it.

What keeps it genuinely relevant is the orexin system’s expanding research surface beyond insomnia. The glymphatic clearance hypothesis has pulled DORAs into Alzheimer’s biology in a serious way. The Ju group at Washington University published mechanistic work suggesting orexin-driven wakefulness disrupts CSF-ISF exchange responsible for amyloid and tau clearance during sleep, making suvorexant an active tool in neurodegeneration research programs rather than just a sleep drug. That hypothesis has been tested clinically (NCT03975114 examined amyloid accumulation under DORA conditions directly). The effect size and durability aren’t established, but the question is real. Similarly, orexin’s role in reward circuitry and drug-seeking behavior has made suvorexant a useful pharmacological probe in addiction neuroscience, where blocking orexin signaling attenuates cue-induced reinstatement in preclinical models.

We think the honest framing for a research library is this: suvorexant is a high-quality reference compound for orexin biology, with excellent evidence quality for its approved indication and early-but-credible signals in neurodegeneration and addiction circuits. What we don’t love is that the most compelling orexin research right now tends to treat suvorexant as a comparator or proof-of-concept tool rather than the object of study itself. If your program is centered on orexin system biology, it’s an important reagent. If you’re hunting the frontier of the sleep-cognition-longevity space, the orexin angle is genuinely interesting but suvorexant is the well-characterized older member of a class that’s rapidly gaining better-optimized successors. Schedule IV. Research-use context only.

Novelty

35

Mechanism promise

60

In-category differentiation

45

Evidence quality

75

Translational signal

72

Research bench value

65

Rationale Suvorexant scores well on evidence and translational signal as a phase-3-backed FDA-approved drug, but twelve years post-approval its novelty is largely spent and newer DORAs (lemborexant, daridorexant) address its PK weaknesses; what keeps the score from collapsing further is the orexin system’s emerging roles in neurodegeneration and addiction, where suvorexant still functions as the reference probe.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Dual orexin receptor antagonist

A dual orexin receptor antagonist (DORA) FDA-approved as Belsomra for insomnia, the first commercialized of the DORA class.

Abstract

Suvorexant (Belsomra; MK-4305; CAS 1030377-33-3; molecular formula C23H23ClN6O2; molecular weight 450.92) is a dual orexin receptor (OX1R, OX2R) antagonist developed by Merck and approved by the FDA in 2014 for insomnia. The compound was the first commercialized DORA. Mechanism is competitive antagonism at orexin-A (hypocretin-1) and orexin-B (hypocretin-2) binding sites on OX1R and OX2R, attenuating orexinergic wakefulness signaling without GABAergic hypnotic effects. Pharmacokinetics: plasma half-life 12 hours; CYP3A4 metabolism. Approved doses are 5 to 20 mg at bedtime. Schedule IV.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-150Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Lemborexant

Plain-language summaryIntrigue 72 / 100

Lemborexant, sold as Dayvigo, is a second-generation dual orexin receptor antagonist with improved selectivity for OX2 over OX1. FDA-approved for insomnia in 2019. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

45/100

Second DORA with refined PK but no novel mechanism; useful clinically, limited bench excitement

Look, the DORA class is genuinely interesting biology. Blocking orexin signaling to let sleep initiate naturally is a fundamentally more elegant approach than hammering GABA-A with benzos or Z-drugs, and the orexin system touches enough downstream biology (metabolism, reward, arousal, thermoregulation) that serious investigators are still mapping its reach. We like that framing. The problem is that suvorexant already got there in 2014, established the mechanism, and built the early research scaffolding. Lemborexant is the second car in the lot.

The clinical differentiation is real but modest. Lemborexant has a somewhat faster-declining active fraction than suvorexant, which translated into statistically improved next-day psychomotor performance in the SUNRISE-1 and SUNRISE-2 trials. Eisai ran solid Phase 3 RCTs; the FDA approved it in 2019. Evidence quality is genuinely good for an insomnia drug, and the clinical signal is clear: it works, it’s well-tolerated, next-day grogginess is less of a problem than with older agents. That earns points. But those points are clinical pharmacology points, not research frontier points.

Here’s the thing: from a bench perspective, what does lemborexant let you do that suvorexant doesn’t? Both are competitive dual OX1R/OX2R antagonists. If you’re using a DORA as a probe to dissect orexin circuit biology, suvorexant has a larger research literature behind it and more years of investigator familiarity. Daridorexant (Quviviq) arrived in 2022 with additional comparative data. Lemborexant sits in the middle of a growing class without claiming either first-mover status or uniquely differentiated pharmacology. For any serious research program building around orexin biology, theres more leverage in selective OX1R or OX2R ligands (SB-334867, EMPA, JNJ-61393178) than in a second-in-class approved DORA.

We don’t want to dismiss the compound entirely. The orexin system research space is active and still has real open questions: the OX1R-versus-OX2R contribution to different sleep architecture features, cross-talk with the HPA axis, the metabolic regulation angle. A well-characterized approved DORA does have utility as a reference compound in that work. But lemborexant specifically adds little that suvorexant doesn’t already provide as a probe, and that limits its research bench value meaningfully.

Honestly, this is a compound that belongs in a clinical pharmacist’s formulary more than on a research scientist’s priority list. The score reflects a real, approved, well-evidenced drug with solid mechanism credentials in a class that matters, discounted heavily for being second-in-class with no novel angle worth chasing in 2024 bench science.

Novelty

35

Mechanism promise

52

In-category differentiation

28

Evidence quality

72

Translational signal

58

Research bench value

28

Rationale Lemborexant earns real marks for solid Phase 3 RCT evidence and a mechanistically elegant class (DORA), but it’s the second approved compound in a mechanism suvorexant already pioneered, and its differentiation story is almost entirely pharmacokinetic rather than pharmacodynamic. The schedule IV cap (75 max) doesn’t bind since the rubric naturally lands well below it.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Dual orexin receptor antagonist

A second DORA FDA-approved as Dayvigo (2019) for insomnia, with shorter half-life and reduced next-day residual effects than suvorexant.

Abstract

Lemborexant (Dayvigo; E2006; CAS 1369764-02-2) is a dual orexin receptor antagonist developed by Eisai and approved by the FDA in 2019 for insomnia. The compound has shorter plasma half-life (17 to 19 hours, but the active fraction declines more rapidly than with suvorexant) and reduced next-day residual sedation in clinical trials. Mechanism is the same as suvorexant: competitive OX1R and OX2R antagonism. Approved doses are 5 to 10 mg at bedtime. Schedule IV.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-151Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.